Myriad facing competition post-SCOTUS, as myRisk doubts raised
This article was originally published in Clinica
Executive Summary
Myriad Genetics is already facing competition from rivals keen to cash in on the recent US Supreme Court decision that DNA is not patentable, but complementary DNA (cDNA) is. The company was defending its patents on the BRCA1 and BRCA2 genes, which are used in its flagship BRACAnalysis test to evaluate the risk of a woman developing hereditary breast or ovarian cancer.